Oh to be listed in Australia.
With solid pipeline (by Australian biotech standards), availability of R&D grants, good cash position along with assets like Inavir and Relenza, we'd shoot the lights out.
BTA Price at posting:
57.0¢ Sentiment: None Disclosure: Held
